{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:20Z","timestamp":1793459660452,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018703","name":"European Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016308","name":"Public Investment Bank France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007353","name":"Fondation J\u00e9r\u00f4me Lejeune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.molmet.2025.102242","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:05:18Z","timestamp":1756451118000},"page":"102242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes"],"prefix":"10.1016","volume":"101","author":[{"given":"Romane","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Tolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Picot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tourrel-Cuzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Ouahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dairou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Deau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias F.","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-1525","authenticated-orcid":false,"given":"Jamileh","family":"Movassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Uzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.molmet.2025.102242_bib1","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.2337\/diabetes.51.2007.S212","article-title":"Accurate assessment of beta-cell function: the hyperbolic correction","volume":"51","author":"Bergman","year":"2002","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/nyas.12031","article-title":"Islet \u03b2 cell mass in diabetes and how it relates to function, birth, and death","volume":"1281","author":"Weir","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ddmod.2007.11.006","article-title":"Models for pharmacological activation of beta-cell regeneration in diabetes","volume":"4","author":"Movassat","year":"2007","journal-title":"Drug Discov Today Dis Model"},{"key":"10.1016\/j.molmet.2025.102242_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/376509","article-title":"Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass","volume":"2011","author":"Portha","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.molmet.2025.102242_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101754","article-title":"An update on pancreatic regeneration mechanisms: searching for paths to a cure for type 2 diabetes","volume":"74","author":"Soldovieri","year":"2023","journal-title":"Mol Metabol"},{"issue":"6","key":"10.1016\/j.molmet.2025.102242_bib7","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1021\/acs.jmedchem.0c02050","article-title":"DYRK1A inhibitors as potential therapeutics for \u03b2-Cell regeneration for diabetes","volume":"64","author":"Kumar","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.molmet.2025.102242_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115521","article-title":"Function and inhibition of DYRK1A: emerging roles of treating multiple human diseases","volume":"212","author":"Yang","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"755","key":"10.1016\/j.molmet.2025.102242_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3456","article-title":"Harmine and exendin-4 combination therapy safely expands human \u03b2 cell mass in vivo in a mouse xenograft system","volume":"16","author":"Rosselot","year":"2024","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.molmet.2025.102242_bib10","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.3390\/ijms22116047","article-title":"Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-Like kinases (CLKs) in human disease, an overview","volume":"22","author":"Lindberg","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.molmet.2025.102242_bib11","first-page":"449","article-title":"DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles","volume":"25","author":"Aranda","year":"2011","journal-title":"FASEB (Fed Am Soc Exp Biol) J: Offic Public Feder Am Soc Exper Biol"},{"key":"10.1016\/j.molmet.2025.102242_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117925","article-title":"A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)","volume":"113","author":"Gehlot","year":"2024","journal-title":"Bioorg Med Chem"},{"issue":"16","key":"10.1016\/j.molmet.2025.102242_bib13","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.3390\/ijms23169355","article-title":"The omnipresence of DYRK1A in human diseases","volume":"23","author":"Deboever","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.molmet.2025.102242_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nm.3820","article-title":"A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication","volume":"21","author":"Wang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.molmet.2025.102242_bib15","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1038\/ncomms9372","article-title":"Inhibition of DYRK1A and GSK3B induces human \u03b2-cell proliferation","volume":"6","author":"Shen","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132594","article-title":"Pharmacologic and genetic approaches define human pancreatic \u03b2 cell mitogenic targets of DYRK1A inhibitors","volume":"5","author":"Ackeifi","year":"2020","journal-title":"JCI Insight"},{"issue":"16","key":"10.1016\/j.molmet.2025.102242_bib17","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.3390\/ijms22169083","article-title":"Diabetic kinome Inhibitors-A new opportunity for \u03b2-Cells restoration","volume":"22","author":"Pucelik","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.molmet.2025.102242_bib18","article-title":"Human beta cell regenerative drug therapy for diabetes: past achievements and future challenges","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molcel.2013.09.009","article-title":"Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle","volume":"52","author":"Chen","year":"2013","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.molmet.2025.102242_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2337\/diabetes.54.3.712","article-title":"Overexpression of cyclin D1 in pancreatic beta-cells in vivo results in islet hyperplasia without hypoglycemia","volume":"54","author":"Zhang","year":"2005","journal-title":"Diabetes"},{"issue":"15","key":"10.1016\/j.molmet.2025.102242_bib21","doi-asserted-by":"crossref","first-page":"10694","DOI":"10.1021\/acs.jmedchem.3c00884","article-title":"Leucettinibs, a class of DYRK\/CLK kinase inhibitors inspired by the marine sponge natural product leucettamine B","volume":"66","author":"Deau","year":"2023","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.molmet.2025.102242_bib22","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1021\/acs.jmedchem.2c02068","article-title":"Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases","volume":"66","author":"Lindberg","year":"2023","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s42003-020-0795-6","article-title":"An isothermal shift assay for proteome scale drug-target identification","volume":"3","author":"Ball","year":"2020","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bmc.2010.11.041","article-title":"Synthesis and evaluation of \u03b2-carboline derivatives as potential monoamine oxidase inhibitors","volume":"19","author":"Reniers","year":"2011","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"10.1016\/j.molmet.2025.102242_bib25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/cmdc.201600539","article-title":"Structure-based design and synthesis of harmine derivatives with different selectivity profiles in kinase versus monoamine oxidase inhibition","volume":"12","author":"B\u00e1lint","year":"2017","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/JOE-19-0239","article-title":"Implication of glycogen synthase kinase 3 in diabetes-associated islet inflammation","volume":"244","author":"Pitasi","year":"2020","journal-title":"J Endocrinol"},{"key":"10.1016\/j.molmet.2025.102242_bib27","article-title":"Lithium treatment mitigates the diabetogenic effects of chronic cortico-therapy","volume":"164","author":"Delangre","year":"2023","journal-title":"Biom Pharma Biom Pharma"},{"issue":"10","key":"10.1016\/j.molmet.2025.102242_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/md15100316","article-title":"Marine-derived 2-Aminoimidazolone alkaloids. Leucettamine B-Related polyandrocarpamines inhibit mammalian and protozoan DYRK & CLK kinases","volume":"15","author":"Loa\u00ebc","year":"2017","journal-title":"Mar Drugs"},{"issue":"12","key":"10.1016\/j.molmet.2025.102242_bib29","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1021\/jm200274d","article-title":"Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing","volume":"54","author":"Debdab","year":"2011","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.molmet.2025.102242_bib30","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/jm301034u","article-title":"Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B","volume":"55","author":"Tahtouh","year":"2012","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.molmet.2025.102242_bib31","first-page":"365","article-title":"Beta-cell mass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent diabetes mellitus","volume":"21","author":"Movassat","year":"1995","journal-title":"Diabete Metab"},{"issue":"5","key":"10.1016\/j.molmet.2025.102242_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tem.2004.05.001","article-title":"Generating new pancreas from old","volume":"15","author":"Hardikar","year":"2004","journal-title":"Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab)"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib33","article-title":"DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis","volume":"2","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2015","journal-title":"Molecular Cellular Oncol"},{"issue":"10","key":"10.1016\/j.molmet.2025.102242_bib34","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-020-05184-7","article-title":"Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies","volume":"63","author":"Bellin","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.molmet.2025.102242_bib35","first-page":"68","article-title":"Pathogenesis of type 2 diabetes in Japan and East Asian populations: basic and clinical explorations. Proceedings of the Japan academy","volume":"101","author":"Seino","year":"2025","journal-title":"Series B, Phys Bio Sci"},{"issue":"2","key":"10.1016\/j.molmet.2025.102242_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1742-4658.2010.07956.x","article-title":"Activation, regulation, and inhibition of DYRK1A","volume":"278","author":"Becker","year":"2011","journal-title":"FEBS J"},{"issue":"2","key":"10.1016\/j.molmet.2025.102242_bib37","first-page":"92","article-title":"Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor","volume":"2","author":"Handforth","year":"2012","journal-title":"Tremor Other Hyper Move"},{"issue":"9","key":"10.1016\/j.molmet.2025.102242_bib38","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1210\/en.2018-00083","article-title":"CC-401 promotes \u03b2-Cell replication via pleiotropic consequences of DYRK1A\/B inhibition","volume":"159","author":"Abdolazimi","year":"2018","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.molmet.2025.102242_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224344","article-title":"Identification of a small molecule that stimulates human \u03b2-cell proliferation and insulin secretion, and protects against cytotoxic stress in rat insulinoma cells","volume":"15","author":"Hohmeier","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.molmet.2025.102242_bib40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature","volume":"27","author":"Nguyen","year":"2017","journal-title":"Expert Opin Ther Pat"},{"issue":"23","key":"10.1016\/j.molmet.2025.102242_bib41","doi-asserted-by":"crossref","first-page":"15648","DOI":"10.1021\/acs.jmedchem.3c01888","article-title":"Chemical, biochemical, cellular, and physiological characterization of Leucettinib-21, a Down syndrome and alzheimer's disease drug candidate","volume":"66","author":"Lindberg","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.molmet.2025.102242_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102815","article-title":"Pancreatic \u03b2-cell remodeling in health and aging: lessons from rodents and humans","volume":"110","author":"Darwish","year":"2025","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.molmet.2025.102242_bib43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/978-90-481-3271-3_21","article-title":"Islet structure and function in the GK rat","volume":"654","author":"Portha","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2008.06.013","article-title":"The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?","volume":"297","author":"Portha","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.molmet.2025.102242_bib45","doi-asserted-by":"crossref","unstructured":"Akash, M.S.H., Rehman, K., Chen, S., n.d. Goto-kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev 9(5): 387\u2013396, Doi: 10.2174\/15733998113099990069.","DOI":"10.2174\/15733998113099990069"},{"issue":"Suppl 2","key":"10.1016\/j.molmet.2025.102242_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1463-1326.2007.00787.x","article-title":"Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans","volume":"9","author":"Ostenson","year":"2007","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.molmet.2025.102242_bib47","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2022e11910","article-title":"A short review on the features of the non-obese diabetic Goto-Kakizaki rat intestine","volume":"55","author":"Gimenes","year":"2022","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.molmet.2025.102242_bib48","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41467-021-21308-y","article-title":"The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary syndrome","volume":"12","author":"Bourgneuf","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/JOE-19-0239","article-title":"Implication of glycogen synthase kinase 3 in diabetes-associated islet inflammation","volume":"244","author":"Pitasi","year":"2020","journal-title":"J Endocrinol"},{"issue":"11","key":"10.1016\/j.molmet.2025.102242_bib50","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac156","article-title":"Sex differences in the molecular programs of pancreatic cells contribute to the differential risks of type 2 diabetes","volume":"163","author":"Yong","year":"2022","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.molmet.2025.102242_bib51","article-title":"Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors","volume":"5","author":"Karakose","year":"2024","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.molmet.2025.102242_bib52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2009.05.035","article-title":"The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells","volume":"138","author":"Collombat","year":"2009","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.molmet.2025.102242_bib53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cmet.2018.07.002","article-title":"GABA and artesunate do not induce pancreatic \u03b1-to-\u03b2 cell transdifferentiation in vivo","volume":"28","author":"Ackermann","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.molmet.2025.102242_bib54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cmet.2017.10.002","article-title":"Artemether does not turn \u03b1 cells into \u03b2 cells","volume":"27","author":"van der Meulen","year":"2018","journal-title":"Cell Metab"},{"issue":"7109","key":"10.1016\/j.molmet.2025.102242_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature05097","article-title":"Calcineurin\/NFAT signalling regulates pancreatic beta-cell growth and function","volume":"443","author":"Heit","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.molmet.2025.102242_bib56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2337\/diabetes.51.3.691","article-title":"NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1","volume":"51","author":"Lawrence","year":"2002","journal-title":"Diabetes"},{"issue":"29","key":"10.1016\/j.molmet.2025.102242_bib57","doi-asserted-by":"crossref","first-page":"26751","DOI":"10.1074\/jbc.M503158200","article-title":"ERK1\/2-dependent activation of transcription factors required for acute and chronic effects of glucose on the insulin gene promoter","volume":"280","author":"Lawrence","year":"2005","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.molmet.2025.102242_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166509","article-title":"Kynurenine-3-monooxygenase expression is activated in the pancreatic endocrine cells by diabetes and its blockade improves glucose-stimulated insulin secretion","volume":"1868","author":"Liu","year":"2022","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"key":"10.1016\/j.molmet.2025.102242_bib59","first-page":"230","article-title":"O-GlcNAcylation links ChREBP and FXR to glucose-sensing","volume":"5","author":"Benhamed","year":"2014","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.molmet.2025.102242_bib60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tem.2013.01.003","article-title":"Novel insights into ChREBP regulation and function","volume":"24","author":"Filhoulaud","year":"2013","journal-title":"Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab)"},{"issue":"2","key":"10.1016\/j.molmet.2025.102242_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tins.2012.12.005","article-title":"Hypothalamic control of energy balance: insights into the role of synaptic plasticity","volume":"36","author":"Dietrich","year":"2013","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.1016\/j.molmet.2025.102242_bib62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.cell.2016.07.028","article-title":"Astrocytic insulin signaling couples brain glucose uptake with nutrient availability","volume":"166","author":"Garc\u00eda-C\u00e1ceres","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.molmet.2025.102242_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102079","article-title":"Chemogenetic engagement of different GPCR signaling pathways segregates the orexigenic activity from the control of whole-body glucose metabolism by AGRP neurons","volume":"91","author":"Espinal Abreu","year":"2025","journal-title":"Mol Metabol"},{"issue":"5","key":"10.1016\/j.molmet.2025.102242_bib64","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1460-9568.2008.06092.x","article-title":"The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb\/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development","volume":"27","author":"H\u00e4mmerle","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"8","key":"10.1016\/j.molmet.2025.102242_bib65","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gutjnl-2018-316128","article-title":"DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth","volume":"68","author":"Luna","year":"2019","journal-title":"Gut"},{"issue":"s1","key":"10.1016\/j.molmet.2025.102242_bib66","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3233\/JAD-240078","article-title":"Leucettinib-21, a DYRK1A kinase inhibitor as clinical drug candidate for alzheimer's disease and Down syndrome","volume":"101","author":"Meijer","year":"2024","journal-title":"J Alzheim Dis: JAD"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:51:10Z","timestamp":1772898670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877825001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":66,"alternative-id":["S2212877825001498"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102242","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102242"}}